title: Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
abstract: BACKGROUND
  Several lines of evidence suggest that the proliferation of ovarian carcinoma might be stimulated by gonadotrophins. A number of Phase I/Phase II clinical trials have reported that the suppression of endogenous luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone (LHRH) analogs induced objective remissions and/or disease stabilization in 10-30% of patients with advanced refractory ovarian carcinoma. The current study was performed to evaluate whether the addition of LHRH agonist treatment to standard platinum-based chemotherapy could prolong survival of patients with surgically treated Stage III or IV epithelial ovarian carcinoma.
  
  
  METHODS
  One hundred and thirty-five patients with Stage III or IV epithelial ovarian carcinoma participated in this prospective randomized double blind trial. After cytoreductive surgery, 69 patients received monthly injections of a depot preparation of the LHRH agonist [D-Trp6] LHRH (triptorelin, 3.75 mg) and 66 patients received placebo until their deaths or termination of trial, respectively. All patients were treated with a standard platinum-based chemotherapy, and, if necessary, with second- or third-line cytotoxic regimens.
  
  
  RESULTS
  Endogenous gonadotrophins were reliably suppressed in patients treated with triptorelin. However, their progression free and overall survival were not significantly different from that of patients receiving placebo injections (statistical power > 80% for a difference between both groups of > or = 20%).
  
  
  CONCLUSIONS
  The results of this trial suggest that the suppression of endogenous gonadotrophins by conventional doses of an LHRH agonist produces no relevant beneficial effects in patients with advanced ovarian carcinoma who receive standard surgical cytoreduction and cytotoxic chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Philipps University, Marburg, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Emons
authors.forename: O
authors.initials: O
authors.lastname: Ortmann
authors.forename: H M
authors.initials: HM
authors.lastname: Teichert
authors.forename: H
authors.initials: H
authors.lastname: Fassl
authors.forename: U
authors.initials: U
authors.lastname: Löhrs
authors.forename: S
authors.initials: S
authors.lastname: Kullander
authors.forename: A
authors.initials: A
authors.lastname: Kauppila
authors.forename: D
authors.initials: D
authors.lastname: Ayalon
authors.forename: A
authors.initials: A
authors.lastname: Schally
authors.forename: F
authors.initials: F
authors.lastname: Oberheuser
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D004311:Double-Blind Method; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011446:Prospective Studies; D016019:Survival Analysis; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone